Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05237271 · ClinicalTrials.gov registry record · NA
Clinical Utility Trial for the SomaLogic CVD-T2D Test
A NA study, sponsored by Qure Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 251
- Enrollment target
NCT05237271: Completed NA study, sponsored by Qure Healthcare.
NCT05237271 is a NA study that has completed, run by Qure Healthcare. The registered enrollment target is 251 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05237271, a NA study, has completed, sponsored by Qure Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 251 participants
- Enrollment target
Study Summary
QURE will use its CPV technology in a randomized controlled trial to measure how SomaLogic's diagnostic test (the Cardiovascular Disease in Type 2 Diabetes) changes clinical practice and improves patient outcomes.
Primary Outcome
Difference-in-differences regression analysis between the control and the intervention groups' physicial exam, workup, diagnosis, and treatment cardiovascular risk in patients with type 2 diabetes, as measured by the participants diagnostic and treatment CPV case domain scores. In each CPV, participants' care recommendations are evaluated against evidence-based care scoring criteria which can sum from 0 to a high potential score of up to 100 percent in each domain, where higher scores mean bette
Interventions
- OTHER Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)
- OTHER Educational Materials on the CVD-T2D and Bundled Metabolic Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2022-08-15 |
| Phase | NA |
What the finished NCT05237271 record still lists
NCT05237271 is an interventional study that assigns participants to a tested intervention. The registered 251 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D) is the first listed.
NCT05237271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05237271 about?
NCT05237271 is a clinical study titled "Clinical Utility Trial for the SomaLogic CVD-T2D Test". QURE will use its CPV technology in a randomized controlled trial to measure how SomaLogic's diagnostic test (the Cardiovascular Disease in Type 2 Diabetes) changes clinical practice and improves patient outcomes.
What is the current status of trial NCT05237271?
This trial is currently completed. It is a NA study. The enrollment target is 251 participants. The study started on 2022-03-15. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT05237271?
The interventions under investigation include: Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D) (OTHER), Educational Materials on the CVD-T2D and Bundled Metabolic Panel (OTHER).
Who is sponsoring clinical trial NCT05237271?
This trial is sponsored by Qure Healthcare, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05237271's enrollment target sits among peer trials
251 410th of 2000 higher than 1,591 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06043817 · 251 participants · Phase 1
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI